|

Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

RECRUITINGSponsored by Peking University First Hospital
Actively Recruiting
SponsorPeking University First Hospital
Started2025-03-19
Est. completion2027-08-31
Eligibility
Age50 Years+
View on ClinicalTrials.gov →

NCT06924359

Summary

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Eligibility

Age: 50 Years+
Inclusion Criteria:

* Male or female participants aged ≥ 50 years;
* Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
* Signed informed consent form

Exclusion Criteria:

* Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
* Inability to cooperate with cognitive assessments;
* Refusal to undergo blood sampling.

Conditions2

Alzheimer's Disease (AD)Alzheimer's Disease

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.